Patent ID: 11912777
Assignee: NANJING LEADS BIOLABS CO., LTD.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A  G | IPC A  C  G

Claim 13:
14. The anti-TNFR2 antibody or antigen-binding fragment thereof according to claim 1, which has one or more of the following properties:
(i) binding to human and/or cynomolgus TNFR2 protein or the fragment thereof in vitro with high affinity;
(ii) binding to human and/or cynomolgus TNFR2 expressed on cell surface;
(iii) blocking the interaction/binding between TNF-α and human and/or cynomolgus TNFR2 expressed on cells;
(iv) activating T-cells
(v) stimulating a downstream signal pathway of TNFR2;
(vi) enhancing an immune-response;
(vii) not inducing antibody-dependent cellular cytotoxicity (ADCC) effects on induced T cells;
(viii) having anti-tumor effects.